Search results for Brodalumab
Brodalumab, Abbexa, abx831223
Brodalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17RA/CD217, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Brodalumab Biosimilar - Research Grade, ichor.bio, ICH5060
Detects human IL-17RA. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Brodalumab.
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.